EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HLS Therapeutics's enterprise value is $176.21 Mil.
HLS Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $12.88 Mil. Therefore, HLS Therapeutics's EV-to-EBITDA for today is 13.68.
The historical rank and industry rank for HLS Therapeutics's EV-to-EBITDA or its related term are showing as below:
HLTRF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.74 Med: 10.07 Max: 32.98
Current: 13.68
During the past 13 years, the highest EV-to-EBITDA of HLS Therapeutics was 32.98. The lowest was -0.74. And the median was 10.07.
HLTRF's EV-to-EBITDA is ranked better than 50.14% of 708
companies
in the Drug Manufacturers industry
Industry Median: 13.88
vs HLTRF: 13.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), HLS Therapeutics's stock price is $3.56.
HLS Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.850. Therefore, HLS Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
HLS Therapeutics EV-to-EBITDA Historical Data
The historical data trend for HLS Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's EV-to-EBITDA falls into.
HLS Therapeutics EV-to-EBITDA Calculation
HLS Therapeutics's EV-to-EBITDA for today is calculated as:
HLS Therapeutics's current Enterprise Value is $176.21 Mil.
HLS Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HLS Therapeutics's PE Ratio for today is calculated as:
HLS Therapeutics's share price for today is $3.56.
HLS Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of HLS Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
HLS Therapeutics (HLS Therapeutics) Business Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HLTRF has been successfully added to your 